










Supplementary Materials: FDA-Approved Small Molecules in 2022: Clinical uses and Their Synthesis






Davide Benedetto Tiz *, Luana Bagnoli, Ornelio Rosati, Francesca Marini, Claudio Santi and Luca Sancineto*

Content:

Table describing the names of the 15 molecules approved by FDA in 2022 (Table S1)	Pages 1-4
Global sales forecast in 2026 (*2028 for some drugs) (Figure S1)	Page 4
References	Page 5

Name	Chemical structure	Therapeutic indication
Daridorexant		insomnia
Abrocitinib		atopic dermatitis (AD)
Mitapivat		hereditary hemolytic anemias
Pacritinib		high-risk primary or secondary myelofibrosis

Ganaxolone		seizures in cyclin-dependent kinase-like 5 deficiency disorder
Lutetium (¹⁷⁷Lu) vipivotide tetraxetan		specific membrane antigen-positive metastatic castration-resistant prostate cancer
Oteseconazole		recurrent vulvovaginal candidiasis (RVVC) in females
Mavacamten		obstructive hypertrophic cardiomyopathy
Vonoprazan		<i>Helicobacter pylori</i> infection (in combination with amoxicillin and clarithromycin)

Tapiranof		plaque psoriasis
Deucravacitinib		plaque psoriasis
Gadopiclenol		detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body
Oomidenepag isopropyl		reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Taurursodiol		amyotrophic lateral sclerosis (ALS) in combination with sodium phenylbutyrate


Futibatinib		intrahepatic cholangiocarcinoma
-------------	---	---------------------------------

Table S1. Table describing the names of the 15 molecules approved by FDA in 2022. Their structures and therapeutic use are provided as well [1].




Figure S1. Forecasted global sales for 2022 FDA-approved drugs (in million \$ in 2026). Values for mavacamten and vonoprazan are meant for 2028. Data for oteseconazole, tapinarof, gadopicleanol, and futibatinib were not available [2-4].

References:

1. Novel Drug Approvals for 2022|FDA. Available online: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2022> (accessed on 24 October 2022).
2. Urquhart, L. FDA New Drug Approvals in Q1 2022. *Nat. Rev. Drug. Discov.* **2022**, *21*, 329–329, doi:10.1038/d41573-022-00063-9.
3. Urquhart, L. FDA New Drug Approvals in Q2 2022. *Nat. Rev. Drug. Discov.* **2022**, *21*, 550–550, doi:10.1038/d41573-022-00123-0.
4. Brown, A. FDA New Drug Approvals in Q3 2022. *Nat. Rev. Drug Discov.* **2022**, doi:10.1038/d41573-022-00174-3.